<a href="https://www.fiercebiotech.com/biotech/roche-details-oral-serd-giredestrant-first-line-flop-breast-cancer-head-held-high" hreflang="en">ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer</a>
Roche remains optimistic about its oral SERD drug giredestrant despite a disappointing phase 3 trial (persevERA) in first-line breast cancer, citing potential in future studies combining it with CDK4/6 inhibitors for early-stage treatment. The company plans to pursue further research and regulatory applications, emphasizing the drug's significant market potential even after the trial's setback.
Roche remains optimistic about the commercial potential of its oral SERD drug, giredestrant, despite a phase 3 trial failure in first-line breast cancer. The company is banking on the drug's performance in the adjuvant setting, where it has shown a positive treatment effect and plans to test its combination with CDK4/6 inhibitors. This strategic pivot could offer significant opportunities for investment or partnership in the adjuvant breast cancer market, which is larger and involves longer treatment durations.